Pharmacodynamic differences between canagliflozin and dapagliflozin: results of a randomized, double-blind, crossover study.

ABSTRACT: AIMS:To compare the pharmacodynamic effects of the highest approved doses of the sodium glucose co-transporter 2 (SGLT2) inhibitors canagliflozin and dapagliflozin on urinary glucose excretion (UGE), renal threshold for glucose excretion (RTG ) and postprandial plasma glucose (PPG) excursion in healthy participants in a randomized, double-blind, two-period crossover study. METHODS:In each treatment period, participants (n?=?54) received canagliflozin 300?mg or dapagliflozin 10?mg for 4?days (20?min before breakfast). A mixed-meal tolerance test (600?kcal; 75?g glucose) was performed at baseline and on day 4 of each treatment period to assess changes in incremental PPG (PPG?AUC0-2 h ). We measured 24-h UGE and plasma glucose on day 4 to determine 24-h mean RTG . RESULTS:Canagliflozin 300?mg and dapagliflozin 10?mg had similar effects on UGE and RTG for 4?h after dosing, but canagliflozin was associated with higher UGE and greater RTG reductions for the remainder of the day. Mean 24-h UGE was ?25% higher with canagliflozin than with dapagliflozin (51.4 vs. 40.8?g), and 24-h mean RTG was ?0.4 mmol/l (7 mg/dl) lower with canagliflozin than with dapagliflozin (3.79 vs. 4.17 mmol/l; p?

SUBMITTER: Sha S 

PROVIDER: S-EPMC6680204 | biostudies-literature | 2015 Feb

REPOSITORIES: biostudies-literature